However, a point to take into account with regard to SOX2 targeting for GBM treatment is that other SOX2 expressing cell populations as astrocytes, which develop relevant roles in neurogenesis, could be susceptible to the treatments. The gene discussed is SOX2; the disease is glioblastoma.